HKMPF - Hikma Pharmaceuticals PLC (HKMPF) Q4 2023 Earnings Call Transcript
2024-02-22 12:33:03 ET
Hikma Pharmaceuticals PLC (HKMPF)
Q4 2023 Earnings Conference Call
February 22, 2024, 07:00 AM ET
Company Participants
Susan Ringdal - EVP, Strategic Planning and Global Affairs
Riad Mishlawi - CEO
Khalid Nabilsi - CFO
Bill Larkins - Head, Injectable Business
Mazen Darwazah - Head, Branded Business
Brian Hoffmann - Head, Generics Business
Conference Call Participants
Peter Verdult - Citi
James Gordon - JPMorgan
Alistair Campbell - RBC
Emily Field - Barclays
Thibault Boutherin - Morgan Stanley
Max Hermann - Stifel
Victoria Lambert - Berenberg
Peter Verdult - Citi
Presentation
Susan Ringdal
Good morning and good afternoon, everyone. Thank you very much for joining Hikma's 2023 Full Year Results Q&A.
I'm very happy to have Riad Mishlawi, Hikma CEO on the call today along with our CFO, Khalid Nabilsi; Bill Larkins, the Head of our Injectable Business; Mazen Darwazah, the Head of our Branded Business; and Brian Hoffmann, who heads-up our Generics Business. Mazen Darwazah is on the phone. And the rest of us should be on your screen.
We are going to have Riad give some introductory comments and then we will open up for Q&A. So I'll hand over now to Riad. Thanks, Riad.
Riad Mishlawi
Thank you, Susan, and thank you everyone for joining us to discuss the 2023 results.
Before we get to the Q&A, I would like to give you a few high-level thoughts on our 2023 performance and go a little bit on the 2024 outlook. Let me start by saying I'm extremely pleased with our performance in 2023. We have delivered strong growth in both revenue and core operating profits and core profitability.
All three of our business contributed to our growth this year. Let me start with the injectables. Injectables continues to deliver. The revenue was up 6% in 2023 with an impressive and consistent core operating margin to close to 37%, probably one of the highest in the market....
Hikma Pharmaceuticals PLC (HKMPF) Q4 2023 Earnings Call Transcript